The Pharma Letter Podcast — Episode 18 — Focus on rare liver diseases, with Albireo CEO Ron Cooper

Simon Wentworth

31 October 2022

episode18-big

More on this story...

Albireo shares rocket as study sets up second Bylvay approval

12 October 2022

NICE backs NHS use of Albireo's Bylvay for all PFIC types

22 February 2022

Albireo's Bylvay gets FDA green light for PFIC

21 July 2021

Evaluate expects Roche to lead the way in steady pharma growth to 2028

21 October 2022

Related Company News

The week in pharma: action, reaction and insight – week to January 13, 2023

Billion dollar buy adds Albireo to Ipsen's list of strategic takeovers

BRIEF—Albireo's Bylvay gains reimbursed access in France

Albireo shares rocket as study sets up second Bylvay approval

More ones to watch >

More Features in Pharmaceutical

Boosting crinecerfont, Neurocrine draws from gamut of FDA support

1 July 2024

In ALS, Phase II data show two drugs could be better than one

1 July 2024

Merck & Co sees value in novel prostate cancer drug

1 July 2024

Lonza welcomes new CEO Wolfgang Wienand

1 July 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze